Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study digs into why some young adults get advanced colon cancer

NCT ID NCT07563166

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked back at medical records of 500 patients aged 50 or younger diagnosed with colorectal cancer or precancerous growths at a hospital in Shenzhen, China. Researchers compared those with early-stage disease to those with later-stage disease to identify factors linked to more advanced tumors. No treatments or extra tests were given—only existing data was analyzed. The goal is to improve early detection and risk assessment for younger patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify younger patients at higher risk for advanced colorectal cancer, leading to earlier detection and better outcomes.
What could go wrong
This is a retrospective observational study, so it can show associations but not prove cause and effect. The findings may not apply to other hospitals or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Jan 2026

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≤50 years with pathology-confirmed colorectal cancer (any T stage) or high-grade intraepithelial neoplasia (HGIN) diagnosed at Shenzhen Hospital, Southern Medical University between 2016-01-01 and 2025-09-30. This retrospective single-cohort study uses de-identified electronic medical records, endoscopy, imaging, and pathology reports to extract demographics, clinical presentation, lifestyle and family history, laboratory and tumor markers, endoscopic/imaging features, detailed pathology (location, size, differentiation, TNM/AJCC stage, LVI, molecular markers if available), treatments, and follow-up outcomes. No additional patient contact or study interventions; data handled under IRB approval/waiver with secure coding and restricted access.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≤ 50 years * Pathologically confirmed colorectal neoplasia diagnosed at Shenzhen Hospital, Southern Medical University between 2016-01-01 and 2025-09-30, defined as colorectal cancer (any T stage) or high-grade intraepithelial neoplasia (HGIN). * Available source documentation: complete or retrievable clinical record, endoscopy report, and pathology report sufficient to determine diagnosis and stage. * De-identifiable data available for extraction (records can be coded and exported without direct identifiers). * No requirement for additional patient contact (retrospective use of existing records with IRB-approved consent waiver or documented consent per ethics approval). Exclusion Criteria: * Secondary/metastatic colorectal tumor (colorectal involvement proven to be metastasis from another primary site). * Prior history of other active malignancy within the last 5 years that could confound staging or outcomes, unless disease is in long-term remission and clearly documented. * Insufficient documentation to determine pathological diagnosis or T stage (key pathology report missing or illegible). * Critical data missing for primary outcome (e.g., pathology date or staging information) that cannot be resolved after source review. * Duplicate records or irreconcilable data (same patient with conflicting identifiers/records that cannot be reconciled). * Patients who received initial diagnostic or therapeutic care outside the study site with no accessible pathology or endoscopy reports at Shenzhen Hospital.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shenzhen Hospital of Southern Medical University

    Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.